These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 10582687)
1. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Liu WM; Guerra-Vladusic FK; Kurakata S; Lupu R; Kohwi-Shigematsu T Cancer Res; 1999 Nov; 59(22):5695-703. PubMed ID: 10582687 [TBL] [Abstract][Full Text] [Related]
2. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Tsai MS; Shamon-Taylor LA; Mehmi I; Tang CK; Lupu R Oncogene; 2003 Feb; 22(5):761-8. PubMed ID: 12569369 [TBL] [Abstract][Full Text] [Related]
3. Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not -resistant cells. Cmarik JL; Li Y; Ogram SA; Min H; Reeves R; Colburn NH Oncogene; 1998 Jul; 16(26):3387-96. PubMed ID: 9692546 [TBL] [Abstract][Full Text] [Related]
4. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Menendez JA; Mehmi I; Lupu R Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820 [TBL] [Abstract][Full Text] [Related]
5. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Atlas E; Cardillo M; Mehmi I; Zahedkargaran H; Tang C; Lupu R Mol Cancer Res; 2003 Jan; 1(3):165-75. PubMed ID: 12556556 [TBL] [Abstract][Full Text] [Related]
6. A deletion mutant of heregulin increases the sensitivity of breast cancer cells to chemotherapy without promoting tumorigenicity. Atlas E; Bojanowski K; Mehmi I; Lupu R Oncogene; 2003 May; 22(22):3441-51. PubMed ID: 12776196 [TBL] [Abstract][Full Text] [Related]
7. Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex. Singh J; Murata K; Itahana Y; Desprez PY Oncogene; 2002 Mar; 21(12):1812-22. PubMed ID: 11896613 [TBL] [Abstract][Full Text] [Related]
8. In vivo posttranslational modifications of the high mobility group A1a proteins in breast cancer cells of differing metastatic potential. Edberg DD; Bruce JE; Siems WF; Reeves R Biochemistry; 2004 Sep; 43(36):11500-15. PubMed ID: 15350136 [TBL] [Abstract][Full Text] [Related]
9. Effects of epidermal growth factor and estrogen on the regulation of the HMG-I/Y gene in human mammary epithelial cell lines. Holth LT; Thorlacius AE; Reeves R DNA Cell Biol; 1997 Nov; 16(11):1299-309. PubMed ID: 9407002 [TBL] [Abstract][Full Text] [Related]
10. The oncogenic properties of the HMG-I gene family. Wood LJ; Maher JF; Bunton TE; Resar LM Cancer Res; 2000 Aug; 60(15):4256-61. PubMed ID: 10945639 [TBL] [Abstract][Full Text] [Related]
11. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Hou YF; Yuan ST; Li HC; Wu J; Lu JS; Liu G; Lu LJ; Shen ZZ; Ding J; Shao ZM Oncogene; 2004 Jul; 23(34):5799-806. PubMed ID: 15208676 [TBL] [Abstract][Full Text] [Related]
12. Elevated high mobility group-I(Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells. Ram TG; Reeves R; Hosick HL Cancer Res; 1993 Jun; 53(11):2655-60. PubMed ID: 8495429 [TBL] [Abstract][Full Text] [Related]
13. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Tallini G; Dal Cin P Adv Anat Pathol; 1999 Sep; 6(5):237-46. PubMed ID: 10472377 [TBL] [Abstract][Full Text] [Related]
14. A matrix attachment region (MAR)-binding activity due to a p114 kilodalton protein is found only in human breast carcinomas and not in normal and benign breast disease tissues. Yanagisawa J; Ando J; Nakayama J; Kohwi Y; Kohwi-Shigematsu T Cancer Res; 1996 Feb; 56(3):457-62. PubMed ID: 8564952 [TBL] [Abstract][Full Text] [Related]
15. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Townson SM; Sullivan T; Zhang Q; Clark GM; Osborne CK; Lee AV; Oesterreich S Clin Cancer Res; 2000 Sep; 6(9):3788-96. PubMed ID: 10999774 [TBL] [Abstract][Full Text] [Related]
16. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Takaha N; Resar LM; Vindivich D; Coffey DS Prostate; 2004 Jul; 60(2):160-7. PubMed ID: 15162382 [TBL] [Abstract][Full Text] [Related]
17. A molecular role for lysyl oxidase in breast cancer invasion. Kirschmann DA; Seftor EA; Fong SF; Nieva DR; Sullivan CM; Edwards EM; Sommer P; Csiszar K; Hendrix MJ Cancer Res; 2002 Aug; 62(15):4478-83. PubMed ID: 12154058 [TBL] [Abstract][Full Text] [Related]
18. Reduction of human metastatic breast cancer cell aggressiveness on introduction of either form a or B of the progesterone receptor and then treatment with progestins. Sumida T; Itahana Y; Hamakawa H; Desprez PY Cancer Res; 2004 Nov; 64(21):7886-92. PubMed ID: 15520195 [TBL] [Abstract][Full Text] [Related]
19. Expression of the human oestrogen receptor-alpha gene is regulated by promoter F in MG-63 osteoblastic cells. Lambertini E; Penolazzi L; Giordano S; Del Senno L; Piva R Biochem J; 2003 Jun; 372(Pt 3):831-9. PubMed ID: 12659635 [TBL] [Abstract][Full Text] [Related]
20. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Fiucci G; Ravid D; Reich R; Liscovitch M Oncogene; 2002 Apr; 21(15):2365-75. PubMed ID: 11948420 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]